Department of Laboratory Medicine, University of Washington Medical Center, Seattle, WA, USA.
Menopause. 2010 May-Jun;17(3):622-9. doi: 10.1097/gme.0b013e3181cb49e9.
Differences in disease outcomes between users and nonusers of hormone therapy (HT) and between users of estrogen therapy (ET) and users of estrogen + progesterone therapy (EPT) may relate to differences in serum hormone concentrations between these populations. In this study, we examined the response of serum hormone levels in healthy postmenopausal women after 1 year of HT.
A representative subsample of 200 healthy adherent participants from the active and placebo groups of the Women's Health Initiative randomized controlled clinical trials of ET (conjugated equine estrogens 0.625 mg daily) or EPT (ET plus medroxyprogesterone acetate 2.5 mg daily) were selected for the determination of selected sex hormone levels at baseline and 1 year after randomization.
In participants receiving active ET intervention compared with placebo, estrogenic hormone levels increased from baseline to year 1 by 3.6-fold for total estrone, 2.7-fold for total estradiol, and 1.8-fold for bioavailable and free estradiol concentrations. Serum sex hormone-binding globulin concentrations also increased 2.5-fold. In contrast, progesterone levels decreased slightly in women taking exogenous EPT. The response of serum estrogens and sex hormone-binding globulin did not differ substantially with the addition of progesterone. In subgroup analyses, hormone response varied by age, ethnicity, body mass index, smoking status, vasomotor symptoms, and baseline hormone levels.
These data provide a reference point for the serum hormone response to HT and demonstrate that the response of serum estrogens is similar for ET and EPT. The implications of the slight decrease in serum progesterone levels with EPT therapy are uncertain. Potential treatment interactions for estrogenic hormones were identified, which suggest a larger response to HT in women with low endogenous levels.
激素治疗(HT)使用者与非使用者、雌激素治疗(ET)使用者与雌孕激素联合治疗(EPT)使用者之间的疾病结局差异可能与这两种人群的血清激素浓度差异有关。本研究旨在探讨健康绝经后妇女在接受 HT1 年后血清激素水平的反应。
从女性健康倡议随机对照临床试验 ET(结合马雌激素 0.625mg 每日)或 EPT(ET 加醋酸甲羟孕酮 2.5mg 每日)的活性和安慰剂组中,选择了 200 名健康依从性参与者的代表性亚样本,以确定基线和随机分组后 1 年时的部分性激素水平。
与安慰剂相比,接受 ET 活性干预的参与者中,总雌酮、总雌二醇、生物可利用和游离雌二醇浓度分别增加了 3.6 倍、2.7 倍和 1.8 倍,雌激素结合球蛋白浓度也增加了 2.5 倍。相反,服用外源性 EPT 的女性孕激素水平略有下降。添加孕激素对血清雌激素和性激素结合球蛋白的反应没有明显差异。亚组分析表明,激素反应因年龄、种族、体重指数、吸烟状况、血管舒缩症状和基线激素水平而异。
这些数据为 HT 后血清激素反应提供了参考点,并表明 ET 和 EPT 的血清雌激素反应相似。EPT 治疗中血清孕激素水平略有下降的意义尚不确定。已确定了雌激素的潜在治疗相互作用,这表明内源性水平较低的女性对 HT 的反应更大。